Loss of TXNIP enhances peritoneal metastasis and can be abrogated by dual TORC1/2 inhibition.
Spaeth-Cook D, Burch M, Belton R, Demoret B, Grosenbacher N, David J, Stets C, Cohen D, Shakya R, Hays JL, Chen JL.
Spaeth-Cook D, et al.
Oncotarget. 2018 Nov 2;9(86):35676-35686. doi: 10.18632/oncotarget.26281. eCollection 2018 Nov 2.
Oncotarget. 2018.
PMID: 30479697
Free PMC article.